Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epacadostat plus Pembrolizumab in Advanced Melanoma
NCT02752074Phase 3Completed
- Sponsor
- Incyte
- Start
- Jun 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Pembrolizumab + Epacadostat with Pembrolizumab + Placebo (2 arms). Primary endpoints: Progression-free Survival at 24 months and Overall Survival Rate at 6 Months. Started Jun 2016; status: completed.
02
Drugs
epacadostat
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02752074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752074.